These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2696394)

  • 41. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical development of iproplatin (CHIP).
    Creaven PJ; Pendyala L; Madajewicz S
    Drugs Exp Clin Res; 1986; 12(1-3):287-92. PubMed ID: 3732051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide].
    Desoize B; Maréchal F; Cattan A
    Ann Biol Clin (Paris); 1993; 51(2):125-8. PubMed ID: 8214810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Concurrent platinum-based chemotherapy and radiotherapy for locally advanced bladder cancer].
    Nakatsuji H; Yamashita Y; Hashine K; Sumiyoshi Y
    Hinyokika Kiyo; 1999 Nov; 45(11):745-8. PubMed ID: 10637735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
    Hohnloser JH; Schierl R; Hasford B; Emmerich B
    Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Electrospray ionization mass spectrometry of platinum anticancer agents.
    Poon GK; Mistry P; Lewis S
    Biol Mass Spectrom; 1991 Nov; 20(11):687-92. PubMed ID: 1799578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determination of platinum originated from antitumoral drugs in human urine by atomic absorption spectrometric methods.
    da Costa AC; Vieira MA; Luna AS; de Campos RC
    Talanta; 2010 Oct; 82(5):1647-53. PubMed ID: 20875558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
    Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
    J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
    Loh GW; Ting LS; Ensom MH
    Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Platinum derivatives].
    Sasaki Y
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():452-5. PubMed ID: 15658361
    [No Abstract]   [Full Text] [Related]  

  • 53. Extent of cisplatin formation in carboplatin admixtures.
    Perrone RK; Kaplan MA; Bogardus JB
    Am J Hosp Pharm; 1989 Feb; 46(2):258-9. PubMed ID: 2653024
    [No Abstract]   [Full Text] [Related]  

  • 54. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.
    Mathé G; Kidani Y; Segiguchi M; Eriguchi M; Fredj G; Peytavin G; Misset JL; Brienza S; de Vassals F; Chenu E
    Biomed Pharmacother; 1989; 43(4):237-50. PubMed ID: 2675999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
    Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
    J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical pharmacokinetics of carboplatin.
    Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
    J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Level of evidence for therapeutic drug monitoring of cisplatin].
    Hulin A; Royer B; Chatelut E; Le Guellec C;
    Therapie; 2010; 65(3):151-5. PubMed ID: 20699064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
    Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
    Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carboplatin (JM-8, CBDCA). A new platinum compound.
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):1-48. PubMed ID: 2655092
    [No Abstract]   [Full Text] [Related]  

  • 60. [Current progress in cancer chemotherapy for childhood cancer].
    Fujimoto T
    Gan To Kagaku Ryoho; 1992 May; 19(5):579-87. PubMed ID: 1580631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.